WallStreetZenWallStreetZen

NASDAQ: IMUX
Immunic Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$1.25+0.08 (+6.84%)
Updated Mar 25, 2025
IMUX Price
$1.25
Fair Value Price
$1.02
Market Cap
$112.60M
52 Week Low
$0.92
52 Week High
$2.11
P/E
-1.02x
P/B
2.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$96.90M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.57
Operating Cash Flow
-$76M
Beta
1.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

IMUX Overview

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine IMUX's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -9.02% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

D
Value
C
Growth
C
Momentum
C
Sentiment
D
Safety
F
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
IMUX
Ranked#415 of 481

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Protalix Biotherapeutics (PLX)
$2.53A
Jazz Pharmaceuticals (JAZZ)
$135.25A
Niagen Bioscience (NAGE)
$7.52A
View Top Biotech Stocks

Be the first to know about important IMUX news, forecast changes, insider trades & much more!

IMUX News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMUX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMUX ($1.25) is overvalued by 22.19% relative to our estimate of its Fair Value price of $1.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMUX ($1.25) is not significantly undervalued (22.19%) relative to our estimate of its Fair Value price of $1.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMUX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMUX due diligence checks available for Premium users.

Valuation

IMUX fair value

Fair Value of IMUX stock based on Discounted Cash Flow (DCF)

Price
$1.25
Fair Value
$1.02
Overvalued by
22.19%
IMUX ($1.25) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMUX ($1.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMUX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IMUX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.02x
Industry
-116.9x
Market
32.24x

IMUX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.73x
Industry
4.62x
IMUX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IMUX's financial health

Profit margin

Revenue
$0.0
Net Income
-$24.4M
Profit Margin
0%
IMUX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$64.8M
Liabilities
$23.5M
Debt to equity
0.57
IMUX's short-term assets ($63.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMUX's short-term assets ($63.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMUX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IMUX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$20.8M
Investing
-$50.0k
Financing
$0.0
IMUX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IMUX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
IMUXF$112.60M+6.84%-1.02x2.73x
MGNXD$112.93M-8.67%-1.67x0.97x
CHRSD$111.26M+0.84%3.84x-0.84x
GALTD$111.09M+7.27%-2.42x-1.18x
SLSC$110.83M-0.81%-2.44x11.71x
View Top Biotech Stocks

Immunic Stock FAQ

What is Immunic's quote symbol?

(NASDAQ: IMUX) Immunic trades on the NASDAQ under the ticker symbol IMUX. Immunic stock quotes can also be displayed as NASDAQ: IMUX.

If you're new to stock investing, here's how to buy Immunic stock.

What is the 52 week high and low for Immunic (NASDAQ: IMUX)?

(NASDAQ: IMUX) Immunic's 52-week high was $2.11, and its 52-week low was $0.92. It is currently -40.76% from its 52-week high and 35.87% from its 52-week low.

How much is Immunic stock worth today?

(NASDAQ: IMUX) Immunic currently has 90,079,016 outstanding shares. With Immunic stock trading at $1.25 per share, the total value of Immunic stock (market capitalization) is $112.60M.

Immunic stock was originally listed at a price of $480.00 in Apr 17, 2014. If you had invested in Immunic stock at $480.00, your return over the last 10 years would have been -99.74%, for an annualized return of -44.85% (not including any dividends or dividend reinvestments).

How much is Immunic's stock price per share?

(NASDAQ: IMUX) Immunic stock price per share is $1.25 today (as of Mar 25, 2025).

What is Immunic's Market Cap?

(NASDAQ: IMUX) Immunic's market cap is $112.60M, as of Mar 26, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Immunic's market cap is calculated by multiplying IMUX's current stock price of $1.25 by IMUX's total outstanding shares of 90,079,016.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.